A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)
Status:
Terminated
Trial end date:
2016-11-04
Target enrollment:
Participant gender:
Summary
This is a Bayesian designed multi-arm, multi-centre, open label phase II study. The target
sample size of 40 patients will be recruited from up to 8 EU countries, but this may be
revised in light of the interim analysis. Patients with relapsed or metastatic osteosarcoma
will be divided into three treatment groups. They will all either have surgery or a biopsy
before and after six weeks exposure to either Mifamurtide alone, Ifosfamide alone, or
Mifamurtide combined with Ifosfamide. They will then receive further treatment to a maximum
of 42 or 36 weeks in total (depending on Arm), with all patients being able to receive 36
weeks of Mifamurtide treatment.
Phase:
Phase 2
Details
Lead Sponsor:
University of Oxford
Collaborators:
European Commission Millennium: The Takeda Oncology Company National Institute for Health Research, United Kingdom Oxford University Hospitals NHS Trust